Canadian Researchers Find Patients Using Remicade Have Greater Risk of Tuberculosis

photo-2

Patients using Remicade (infliximab) are more susceptible to developing tuberculosis (TB) than individuals using Enbrel (etanercept), states an article written by Canadian researchers.

The peer-reviewed article, which appeared in the April 29 issue of the Canadian Medical Association Journal, also concluded that Remicade may be more potent than other therapeutic agents capable of reactivating TB in patients with a latent form of the disease.

Remicade is a part-human, part-mouse antibody that is prescribed to treat the symptoms of autoimmune disorders such as rheumatoid arthritis and Crohn's Disease.

Autoimmune disorders occur when the body's immune system malfunctions and starts …